Eli Lilly & Co

Insider sale at Eli Lilly shows a routine liquidity move amid a bold $4.5 billion Indiana plant expansion and $8 billion bond issuance, fueling a diversified biotech pipeline and market‑access strategy.

Insider buying at Eli Lilly shows executive confidence in its upcoming Kelonia Therapeutics acquisition, hinting at a stronger oncology portfolio and potential share price rebound.

Insider buying by Eli Lilly’s Yuffa Ilya on Feb 1 shows leadership confidence amid a falling share price, suggesting the stock may be undervalued and poised for long‑term gains.

Executive insider buying at Eli Lilly signals confidence in the company’s oncology, neuroscience pipelines and new Repertoire partnership – a subtle yet positive market cue.

Investor insight: LILLY ENDOWMENT INC sold $95 M of Eli Lilly shares on Jan 7, 2026, sparking brief volatility but underscoring portfolio realignment amid the Ventyx acquisition and Eli Lilly’s robust, diversified pipeline.